SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia

Clinical Biochemistry

Volumn 46, Issue 7-8, 2013, Pages 701-703

  Yang, Jing ^a   Qian, Jun ^a   Yao, Dong ming ^a   Qian, Si xuan ^b   Qian, Wei ^a   Lin, Jiang ^a   Xiao, Gao fei ^a   Wang, Cui zhu ^a   Deng, Zhao qun ^a   Ma, Ji chun ^a   Chen, Xing xing ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; High resolution melting analysis; SF3B1 mutation

Indexed keywords

CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; NUCLEOPHOSMIN; PHOSPHOPROTEIN; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CHINESE; CHRONIC MYELOID LEUKEMIA; CODON; DNA SEQUENCE; GENE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; SF3B1 GENE; SURVIVAL TIME; ASIAN; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; DNA MUTATIONAL ANALYSIS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR;

EID: 84884741125     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.01.023     Document Type: Article

References (10)

1. Döhner H., Gaidzik V.I. Impact of genetic features on treatment decisions in AML. Hematol Am Soc Hematol Educ Program 2011, 2011:36-42.
2. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
3. Grosso A.R., Martins S., Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008, 9:1087-1093.
4. Maciejewski J.P., Padgett R.A. Defects in spliceosomal machinery: a new pathway of leukaemogenesis. Br J Haematol 2012, 158:165-173.
5. Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
6. Qian J., Yao D.M., Lin J., Qian W., Wang C.Z., Chai H.Y., et al. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS One 2012, 7:e45760.
7. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011, 365:1384-1395.
8. Damm F., Kosmider O., Gelsi-Boyer V., Renneville A., Carbuccia N., Hidalgo-Curtis C., et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012, 119:3211-3218.
9. Jeromin S., Bacher U., Bayer K., Dicker F., Eder C., Fasan A., et al. SF3B1 mutations are detectable in 48.9% of acute myeloid leukemia with normal karyotype (AML-NK) and ≥15% ring sideroblasts and are closely related to FLT3-ITD and RUNX1 mutations. Blood 2012, 120:406.
10. Malcovati L., Papaemmanuil E., Bowen D.T., Boultwood J., Della Porta M.G., Pascutto C., et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011, 118:6239-6246.